BIOCON BIOLOGICS GERMANY GMBH

BALANCE SHEET AS AT MARCH 31, 2026

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Notes	March 31, 2026	March 31, 2025
ASSETS			
Non-current assets			
Property, plant and equipment	1	106	155
Capital work-in-progress		184	-
Right-of-use assets	2	1,484	-
Deferred tax asset (net)		138	-
Total non-current assets		**1,912**	**155**
Current assets			
Inventories	3	10,889	8,679
Financial assets			
(i) Trade receivables	4	61,132	27,976
(ii) Cash and cash equivalents	5	21,119	10,657
Other current assets	6	25	268
Total current assets		**93,165**	**47,580**
TOTAL		**95,077**	**47,735**
EQUITY AND LIABILITIES			
Equity			
Equity share capital	7	25	25
Other equity	8	3,379	1,448
Total equity		**3,404**	**1,473**
Non-current liabilities			
Financial liabilities			
Lease liabilities		921	-
Total non-current liabilities		**921**	**-**
Current liabilities			
Financial liabilities			
(i) Trade payables	9	83,160	36,591
(ii) Lease liabilities		587	-
Income-tax liability (net)		1,429	590
Provisions	10	1,509	607
Other current liabilities	11	4,067	8,474
Total current liabilities		**90,752**	**46,262**
TOTAL		**95,077**	**47,735**

BIOCON BIOLOGICS GERMANY GMBH
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Notes	Year ended March 31, 2026	Year ended March 31, 2025
Income			
Revenue from operations	12	1,32,996	72,449
Other operating income	13	1	-
Total revenue		**1,32,997**	**72,449**
Expenses			
Purchases of traded goods	14	1,11,110	59,335
Changes in inventories of traded goods	15	(2,210)	(8,679)
Employee benefits expense	16	12,289	12,483
Finance costs	17	123	-
Depreciation	18	372	-
Other expenses	19	8,419	7,430
Total expenses		**1,30,103**	**70,569**
Profit/(loss) before exceptional item and tax		**2,894**	**1,880**
Exceptional items		148	**-**
Profit/(loss) before tax		**2,746**	**1,880**
Tax expense			
Current tax		953	545
Deferred Tax		(138)	-
Total tax expense		**815**	**545**
Profit/(loss) for the year		**1,931**	**1,335**

BIOCON BIOLOGICS GERMANY GMBH

STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2026

(All amounts in EUR Thousands, except share data and unless otherwise stated)

		Year ended March 31, 2026	Year ended March 31, 2025
I	**Cash flows from operating activities**		
	Profit after tax	**1,931**	**1,335**
	Adjustments to reconcile profit before tax to net cash flows:		
	Unrealised foreign exchange loss	(9)	17
	Tax expense	815	545
	Finance Cost	123	-
	Interest income	(1)	-
	Depreciation and amortisation (net)	372	-
	Operating profit before working capital changes	**3,231**	**1,897**
	Movements in working capital		
	(Increase) in trade receivables	(33,147)	(24,460)
	(Increase) in trade inventories	(2,210)	(8,679)
	Decrease/(Increase) in loans and advances and other assets	243	(266)
	Increase in trade payable, other liabilities and provisions	43,065	41,563
	Cash generated from operations	**11,182**	**10,055**
	Direct taxes paid	(114)	(3)
	Net cash flow generated from operating activities	**11,068**	**10,052**
II	**Cash flows from investing activities**		
	Purchase of tangible assets	(184)	(155)
	Proceeds from sale of property, plant and equipment	23	-
	Net cash flow (used in) investing activities	**(161)**	**(155)**
III	**Cash flows from financing activities**		
	Repayment of Lease Liability	(446)	-
	Interest income from bank deposit	1	-
	Net cash flow (used in) financing activities	**(445)**	**-**
IV	**Net increase in cash and cash equivalents (I + II + III)**	**10,462**	**9,897**
V	Effect of exchange differences on cash and cash equivalents held in foreign currency	-	-
VI	Cash and cash equivalents at the beginning of the period	10,657	759
VII	**Cash and cash equivalents at the end of the period (IV + V +VI)**	**21,119**	**10,657**
	Reconciliation of cash and cash equivalents as per statement of cash flow		
	Cash and cash equivalents		
	Balances with banks - on current accounts	21,119	10,657
	Total cash and cash equivalents [Refer note 5]	**21,119**	**10,657**

BIOCON BIOLOGICS GERMANY GMBH
Notes to financial statements for the year ended March 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

1. Property, plant and equipment and Asset under development

	Computer and Computer Accessories	Total
Gross carrying amount		
At March 31, 2024	**-**	**-**
Additions	155	155
Deletions	-	-
At March 31, 2025	**155**	**155**
Additions	-	-
Deletions	(23)	(23)
At March 31, 2026	**132**	**132**
Accumulated depreciation		
At March 31, 2024	**-**	**-**
Depreciation for the year	-	-
Deletion	-	-
At March 31, 2025	**-**	**-**
Depreciation for the period	**25**	**25**
Deletion	-	-
At March 31, 2026	**25**	**25**
Net carrying amount		
At March 31, 2025	**155**	**155**
At March 31, 2026	**106**	**106**

2. Right-of-use assets

Gross carrying amount	**Vehicles**	**Vehicles**
At March 31, 2024	**-**	**-**
Additions	-	-
As at March 31, 2025	**-**	**-**
Additions	1,831	1,831
As at March 31, 2026	**1,831**	**1,831**
Accumulated depreciation		
At March 31, 2024	**-**	**-**
Depreciation for the year	-	-
As at March 31, 2025	**-**	**-**
Depreciation for the year	347	347
As at March 31, 2026	**347**	**347**
Net carrying amount		
As at March 31, 2025	**-**	**-**
As at March 31, 2026	**1,484**	**1,484**

BIOCON BIOLOGICS GERMANY GMBH
Notes to financial statements for the year ended March 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	March 31, 2026	March 31, 2025
3. Inventories		
Finished Goods	10,889	8,679
	10,889	**8,679**
4. Trade receivables		
Other Receivables		
Unsecured, considered good	61,172	27,976
Allowance for credit loss	(40)	-
	61,132	**27,976**
5. Cash and cash equivalents		
Balances with banks:		
On current accounts	21,119	10,657
	21,119	**10,657**
6. Other current assets		
Prepayments	21	268
Others	4	-
	25	**268**
7. Share capital		
Equity share 25,000 Common stock of EUR 1 each	25	25
	25	**25**
8. Other equity		
Surplus in the statement of profit and loss		
Balance as per the last financial statements	1,448	113
Profit for the period	1,931	1,335
Net surplus in the statement of profit and loss	**3,379**	**1,448**
Total other equity	**3,379**	**1,448**
9. Trade payables	**83,160**	**36,591**
10. Provisions		
Current		
Compensated absences	1,509	607
	1,509	**607**
11. Other liabilities		
Current liabilities		
Statutory liabilities	3,166	7,009
Employee related payables	901	1,465
	4,067	**8,474**

BIOCON BIOLOGICS GERMANY GMBH
Notes to financial statements for the year ended March 31, 2026
(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Year ended March 31, 2026	Year ended March 31, 2025
12. Revenue from operations		
Sale of Products		
Traded Goods	1,26,811	58,146
Sale of Services		
Support service cross charge to Group Companies	6,185	14,303
	1,32,996	**72,449**
13. Other operating income		
Interest income	1	-
	1	**-**
14. Purchase of traded goods	1,11,110	59,335
	1,11,110	**59,335**
15. Changes in inventories of traded goods		
Inventory at the beginning of the year		
Traded goods	8,679	-
Inventory at the end of the year		
Traded goods	10,889	8,679
	(2,210)	**(8,679)**
16. Employee benefits expense		
Salaries, wages and bonus	12,049	12,248
Employee stock compensation expense	226	152
Staff welfare expenses	14	83
	12,289	**12,483**
17.Finance Costs		
Interest on lease obligation	54	-
Interest on loans	69	-
	123	**-**
18. Depreciation		
Amortisation of right to use assets	347	-
Depreciation of tangible assets	25	-
	372	**-**
19. Other expenses		
Rates and taxes	40	13
Rent	750	1,066
Legal and professional fees	2,079	2,096
Repair and Maintenance	326	470
Research and development expenses	-	7
Travelling and conveyance	673	566
Sales promotion expenses	1,910	2,031
Printing and stationery	361	176
Communication expenses	23	9
Miscellaneous expenses	814	180
Foreign exchange fluctuations, net	(9)	17
Distribution expenses	1,257	416
Insurance Charges	155	383
Provision for doubtful debts, net	40	-
	8,419	**7,430**